https://www.mithra.com/wp-content/uploads/2017/10/search.jpg 1333 2000 Mithra Pharmaceuticals https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Mithra Pharmaceuticals2019-12-31 07:30:162019-12-31 01:25:21First patient recruited for Donesta® Phase III Clinical Study in Europe
- Recruitment of the first patient for the second pivotal Donesta® Phase III study conducted in 12 countries in Europe, Russia and South America
- “E4 Comfort” Phase III Clinical Program for Donesta® successfully launched in October 2019 with recruitment of first patient for North American study
- Phase III Program aimed at enrolling approximately 2200 menopausal women with vasomotor symptoms
Liege, Belgium, 31 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the recruitment of the first patient for the second pivotal Phase III Donesta® clinical study. Donesta® is a next generation orally-administered E4-based hormone therapy product candidate for the relief of menopausal vasomotor symptoms (VMS).